
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics is set for long-term success with continued positive sales growth driven by a strong commercialization strategy, increased placement of their robotic systems in BPH surgery centers, and the potential for international expansion. Despite some potential challenges such as handpiece sales and pricing pressure, the company's innovative technology and potential for addressing a larger market opportunity make it a strong investment opportunity. Additionally, the company's positive Q1 results and continued execution of their key strategies provide a strong foundation for future growth.
Bears say
PROCEPT BioRobotics is facing multiple challenges, including increasing competition in the BPH market and lower-than-expected handpiece sales driven by changes in purchasing patterns and inventory levels. This has led management to lower its 2026 revenue guidance and report weaker-than-expected Q4 results, with an adjusted EBITDA loss of $19 million. Despite the company's spot on domestic capital sales and record number of capital sales, there is still concern about the timeframe for sales force reorganization benefits to materialize, making it difficult for investors to ignore the impact of these challenges on PRCT's financials and outlook.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares